TrialReach raised $13.5 million in a Series B round to scale up its clinical trial discovery platform. The system is designed to accelerate enrollment into clinical research by matching patients to appropriate trials.
The long-awaited move toward risk-based monitoring has started. Having introduced its partial source document verification (PSDV) offering back in 2010, Medidata has now reported a 50% year-on-year jump in the number of clients using the technology.
Apple has begun staking its claim to be the de facto standard for remote data collection. The tech giant has reportedly kicked off pilot programs of its HealthKit service at many leading hospitals, positioning it to play a major role in remote patient monitoring for general care and clinical trials.
Merck has joined Novartis, Pfizer and a host of other Big Pharma companies in the Structural Genomics Consortium (SGC), a transatlantic public-private collaboration focused on the 3-D structures of proteins.
The FDA has requested $2 million in President Obama's 2016 budget to build precision medicine-related IT infrastructure. The regulator highlighted cloud computing and data security as areas in which it needs to improve.
Big Data initiatives such as President Obama's precision medicine program and the United Kingdom's 100,000 Genomes Project risk losing public trust unless they consider the moral and legal implications of their work, a report has warned.
President Obama has made the creation of a huge, technically challenging database the centerpiece of his precision medicine proposal. The initiative will draw on existing resources and new studies to gather data on the biology, behavior and health of more than 1 million people.
The U.S. House of Representatives' Energy and Commerce Committee's Subcommittee on Health has laid out its vision for the future of drug and device regulation in a draft bipartisan bill. And the plan has significant implications for the use of health data in R&D and other topics related to biotech IT.
Duke University has expanded its presence on the North Carolina Research Campus to support its work with Google and other partners.
Alexion Pharmaceuticals has turned to Big Data specialist BioXcel for help identifying its next blockbuster rare disease drug. BioXcel is applying its rare disease database to the collaboration, which aims to figure out which indications are most likely to benefit from various therapeutics.
The Google X lab that spawned smart contact lenses and self-driving cars is teaming up with Biogen Idec to unravel patient-to-patient variation in the progression of multiple sclerosis.
Box has added a big-name client just days after pulling off a $175 million IPO. The deal sees AstraZeneca join Allergan and Eli Lilly on the list of major biopharma companies that use Box's cloud content sharing and collaboration tools.
The European Medicines Agency (EMA) has taken another step toward the creation of a database of all suspected adverse reactions reported within its jurisdiction. The EMA laid out the technical details of the system and how it will affect biopharma companies in a 100-page guide it published this week.
Juniper Research analyst James Moar told Outsourcing-Pharma the placing of limits on the types of information that can have medical uses will slow uptake.
Study startup specialist goBalto is preparing to up its game in Asia. The San Francisco, CA-based software developer outlined the strategy after raising $12 million from new backers, including Japan's Mitsui Global Investment.
President Obama has pushed precision medicine and cybersecurity into the national consciousness and toward the top of the legislative agenda. Obama referred to both topics in his State of the Union address, but at this stage more is known about the cybersecurity plan.
Anyone with a passing interest in tech startups is unlikely to be shocked by Silicon Valley VC Andreessen Horowitz listing digital health as one of its top 16 trends. But as one of the organizations with some power over how these trends play out, the reasoning behind Andreessen Horowitz's list makes for interesting reading.
Last year the campaign for Chimerix to give an experimental cancer drug to a 7-year-old gave biopharma firms another reason to be wary of the power of social media. Having seen Chimerix be engulfed by the social media maelstrom, BIO is working to equip small biotechs with the skills they will need if they find themselves in a similar situation.
The deal gives Novartis access to the most active digital health VC team--Rock Health reports Qualcomm Ventures has struck 21 deals since 2011--and further strengthens the ties between the two companies.
10X Genomics has exited stealth mode with $80 million in VC funding and a plan to solve a significant sequencing problem without going head to head with Illumina. The Pleasanton, CA-based startup is set to unveil an add-on for Illumina sequencers that improves their ability to map long reads of DNA.